Boardroom Alpha
Boardroom Alpha
OSG · Current Report (Form 8-K) · Filed April 7, 2026

Octave Specialty Group Inc — Current Report (Form 8-K)

Form
8-K
Filed
April 7, 2026
Period
Apr 1, 2026
Ticker
OSG
Accession
0001628280-26-024072
Boardroom Alpha · Filing insights

Octave secures a $40M additional term loan; total term loans now $139.375M, funding Cirrata UK's minority put rights.

About Octave Specialty Group Inc
Market cap
$233M
1Y TSR
−24.9%
3Y TSR
−27.3%
Board grade
C-
Sector
Financial Services
CEO
Claude Leblanc
Last annual meeting: May 28, 2026 · View full Octave Specialty Group Inc profile →
ambc-20260401

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 1, 2026
Octave Specialty Group, Inc.
(Exact name of Registrant as specified in its charter)

Delaware1-1077713-3621676
(State of incorporation)(Commission
file number)
(I.R.S. employer
identification no.)
40 Wall StreetNew YorkNY10005
(Address of principal executive offices)
(212)
658-7470
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common stock, par value $0.01 per shareOSGNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.



Item 1.01. Entry into a Material Definitive Agreement
First Amendment to Credit Agreement
On April 1, 2026, Octave Specialty Group, Inc. (the “Company”), through its wholly owned subsidiaries Octave Partners LLC, a Delaware limited liability company, Cirrata V LLC, a Delaware limited liability company, Cirrata V UK Limited (“Cirrata UK”), a private limited company incorporated in England and Wales with company number 15854655, Cirrata VI, LLC, a Delaware limited liability company, ArmadaCorp Capital, LLC, a Maryland limited liability company, ArmadaCare, LLC, a Maryland limited liability company, and Armada Administrators LLC, a Maryland limited liability company (collectively, the “Borrowers”), together with the other loan parties, entered into the First Amendment to Credit Agreement and Other Loan Documents (the “First Amendment”) with the lenders signatory thereto (the “Lenders”) and Truist Bank, as administrative agent (in such capacity, the “Administrative Agent”). The First Amendment amends that certain Credit Agreement dated as of October 31, 2025 (“Original Credit Agreement”), by and among the Borrowers, the Lenders party thereto and the Administrative Agent.
The First Amendment provides an additional term loan in an aggregate principal amount of $40,000,000 (the “Additional Term Loan”), which constitutes the same class, type, and tranche as the term loan outstanding under the Original Credit Agreement (the “Existing Term Loan”), and the Additional Term Loan has the same maturity date and interest rate as the Existing Term Loan, and is fully fungible with the Existing Term Loan in all respects. After the First Amendment, the total amount of the outstanding term loans is $139,375,000 as of April 1, 2026. In connection with the First Amendment, the Company pledged its ownership interests in the capital stock of Everspan Holdings, LLC, a Delaware limited liability company.
The proceeds from the Additional Term Loan will be used to, among other things, fund the payment of Cirrata UK’s obligation to honor the put rights exercised in March 2026 by certain minority shareholders of Octave Specialty Limited, a private limited company incorporated in England and Wales.

The description of the First Amendment in this report is qualified in its entirety by reference to the full text of the First Amendment, a copy of which will be filed as an exhibit to the Company's Quarterly Report on form 10-Q for the quarter ended June 30, 2026.
Item 2.03 Creation of a Direct Financial Obligation.
The disclosure set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits. The following exhibits are filed as part of this Current Report on Form 8-K
2


EXHIBIT INDEX
Exhibit
Number
Exhibit Description
101.INS
XBRL Instance Document - the instance document does not appear in the interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH
XBRL Taxonomy Extension Schema Document.
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB
XBRL Taxonomy Extension Label Linkbase Document.
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document.
104
Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags or embedded within the Inline XBRL document
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Octave Specialty Group, Inc.
(Registrant)
Dated:April 7, 2026By:
/s/ Reid Powell
Reid Powell
Assistant General Counsel
3
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Octave Specialty Group Inc (OSG)

Reference

Frequently asked questions

When did Octave Specialty Group Inc file this 8-K?
Octave Specialty Group Inc (OSG) filed this Current Report (Form 8-K) with the SEC on April 7, 2026. The accession number assigned by EDGAR is 0001628280-26-024072.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Octave secures a $40M additional term loan; total term loans now $139.375M, funding Cirrata UK's minority put rights. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Octave Specialty Group Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Octave Specialty Group Inc has filed under CIK 874501, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer